Vascular endothelial growth factor (VEGF) inhibitors gained widespread use in oncology given their ability to limit angiogenesis. However, VEGF inhibitors can lead to a preeclampsia-like syndrome. The renal involvement in preeclampsia is characterized by hypertension and proteinuria. The most common side effect of VEGF inhibitors is a dose dependent hypertension, which has been reported in up to 67% of patients. In addition, pre existing hypertension is often times worsened.